Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Consensus PT from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $15.60.

Several research firms recently commented on YMAB. HC Wainwright lowered their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Truist Financial cut their target price on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Oppenheimer reduced their target price on shares of Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a report on Wednesday, March 5th. Finally, Wedbush restated an "outperform" rating and issued a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brooklyn Investment Group grew its holdings in shares of Y-mAbs Therapeutics by 4,563.8% during the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $46,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Y-mAbs Therapeutics during the 1st quarter worth approximately $49,000. Corton Capital Inc. purchased a new position in Y-mAbs Therapeutics during the 1st quarter worth approximately $55,000. Finally, EntryPoint Capital LLC acquired a new position in Y-mAbs Therapeutics during the first quarter worth approximately $56,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock traded down $0.30 during trading on Monday, reaching $4.63. The company's stock had a trading volume of 161,686 shares, compared to its average volume of 303,310. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11. The stock's 50-day moving average price is $4.42 and its 200 day moving average price is $6.05. The company has a market capitalization of $209.66 million, a price-to-earnings ratio of -8.57 and a beta of 0.52.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $20.90 million during the quarter, compared to the consensus estimate of $19.97 million. On average, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.